Sign inJoin waitlistJoin the waitlist

Jeremy Ramdial

Assistant Professor of Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2019–2020
Internal Medicine
Jackson Memorial Hospital
2013–2016
Leonard M. Miller School of Medicine
2009–2013

Research

CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity
Blood Advances · 2021 · 134 citations
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
Blood · 2021 · 94 citations
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
Haematologica · 2023 · 73 citations

Elizabeth Shpall
90 papers
Richard Champlin
81 papers
Partow Kebriaei
68 papers
Yago Nieto
65 papers
Samer Srour
63 papers
Muzaffar Qazilbash
59 papers
Qaiser Bashir
52 papers
Uday Popat
48 papers
Neeraj Saini
44 papers
Oren Pasvolsky
37 papers · 37 as a fellow
Chitra Hosing
34 papers
Krina Patel
34 papers

Grants

NK Cell Engineering to Target Intracellular Antigens in AML
National Cancer Institute · R01
PI · $442.1K · University of Tx Md Anderson Can Ctr
2026–2031

Clinical trials

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2029
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2029
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2022–2025
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2022–2023